New drug combo for advanced neuroendocrine cancer after first treatment fails
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of chemotherapy (FOLFIRI) plus two immunotherapy drugs (zimberelimab and domvanalimab) for people with advanced neuroendocrine carcinoma that has grown after initial treatment. It aims to see if this new approach works better than standard chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a rare, fast-growing type of neuroendocrine cancer (called poorly differentiated NEC) that started in your digestive system or an unknown location, and standard chemotherapy has stopped working.
- You have at least one tumor that can be measured on a scan and hasn't been treated with radiation before.
- Your overall health is good (ECOG score 0 or 1, meaning you can do most daily activities).
- You agree to use effective birth control during treatment and for several months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a chemotherapy approach in people with metastatic grade 3 (high-grade) neuroendocrine cancer or a related rare mixed tumor. It may help shrink tumors and control disease when standard first treatments have not yet been given.
This trial tests a combination of three drugs for people with advanced neuroendocrine carcinoma that has stopped responding to previous treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial is testing a combination of an immunotherapy drug (QL1706), a targeted therapy (lenvatinib), and chemotherapy for people with advanced neuroendocrine carcinoma that started outside the lungs. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
Hear when a new Carcinoma, Neuroendocrine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.